I think if the P2b trial is randomized, then yes. This is not what's going on with Stimuvax, of course. They created a massive P3 program on a P2b subgroup analysis.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.